

CITATION REPORT

List of articles citing

Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent *Clostridium difficile* infection

DOI: 10.1093/cid/cir632

Clinical Infectious Diseases, 2011, 53, 994-1002.

Source: <https://exaly.com/paper-pdf/49871932/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
829	The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. 2008 , 6, e280		1660
828	The equine intestinal microbiome. 2012 , 13, 121-8		54
827	Fecal microbiota transplantation in relapsing <i>Clostridium difficile</i> infection. 2012 , 5, 403-20		134
826	<i>Clostridium difficile</i> : novel insights on an incessantly challenging disease. 2012 , 25, 405-11		11
825	Current world literature. 2012 , 25, 469-76		
824	<i>Clostridium difficile</i> - state of the art. 2012 , 08, 81-91		6
823	<i>Clostridium difficile</i> colitis: a review. 2012 , 40, 139-48		24
822	<i>Clostridium difficile</i> infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response. 2012 , 3, 121-34		138
821	<i>Clostridium difficile</i> : epidemiology, pathogenesis, management, and prevention of a recalcitrant healthcare-associated pathogen. 2012 , 36, 645-62		48
820	Fecal Bacteriotherapy: A Case Report in an Immunosuppressed Patient with Ulcerative Colitis and Recurrent <i>Clostridium difficile</i> Infection. 2012 , 2012, 810943		19
819	In the Literature. <i>Clinical Infectious Diseases</i> , 2012 , 55, iii-iv	11.6	
818	Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent <i>Clostridium difficile</i> infection. <i>Clinical Infectious Diseases</i> , 2012 , 55, 1652-8	11.6	127
817	Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. 2012 , 12, 611-22		448
816	Genomic approaches to studying the human microbiota. 2012 , 489, 250-6		342
815	Progress with a difficult infection. 2012 , 12, 256-7		5
814	Colonoscopic versus nasogastric fecal transplantation for the treatment of <i>Clostridium difficile</i> infection: a review and pooled analysis. 2012 , 40, 643-8		87
813	Interaction between the intestinal microbiota and host in <i>Clostridium difficile</i> colonization resistance. 2012 , 20, 313-9		171

812	The microbiome as a human organ. 2012 , 18 Suppl 4, 2-4	193
811	Clostridium difficile: Changing Epidemiology, Treatment and Infection Prevention Measures. 2012 , 14, 612-9	17
810	Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient. 2012 , 14, E161-5	82
809	The gut is the epicentre of antibiotic resistance. 2012 , 1, 39	110
808	Infectious causes of chronic diarrhoea. 2012 , 26, 563-71	21
807	Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. 2012 , 107, 1079-87	502
806	Felix d'Herelle and our microbial future. 2012 , 7, 1337-9	7
805	Detection, treatment, and prevention of Clostridium difficile infection. 2012 , 10, 581-92	73
804	Fecal microbiota transplantation: are we opening a can of worms?. 2012 , 143, e19; author reply e19-20	18
803	Reply. 2012 , 143, e19-e20	
802	Clostridium difficile infection: new insights into management. 2012 , 87, 1106-17	98
801	Immune responses to Clostridium difficile infection. 2012 , 18, 658-66	62
800	Hospital-acquired infections. 2012 , 30, 640-644	7
799	Epidemiology, diagnosis and treatment of Clostridium difficile infection. 2012 , 10, 1405-23	53
798	Diversity, stability and resilience of the human gut microbiota. 2012 , 489, 220-30	2919
797	Specific probiotics or 'fecal transplantation'. 2012 , 30 Suppl 3, 81-4	7
796	A Canadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics. 2012 , 26, 457-62	50
795	Faecal microbiota transplant. 2012 , 10, 6-7	3

794	[Treatment of refractory or recurrent Clostridium difficile infection]. 2012 , 60, 71-8	3
793	Therapeutic modulation of microbiota-host metabolic interactions. 2012 , 4, 137rv6	170
792	Microbiota-targeted therapies: an ecological perspective. 2012 , 4, 137rv5	171
791	A complex microworld in the gut: Harnessing pathogen-commensal relations. 2012 , 18, 1190-1	24
790	Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. 2012 , 36, 503-16	229
789	Clostridium difficile infection in the inflammatory bowel disease patient. 2013 , 19, 194-204	96
788	Changing Epidemiology and Control of Clostridium difficile in Older Adults. 2013 , 2, 143-150	
787	Clostridium difficile: a European perspective. 2013 , 66, 115-28	108
786	Fecal microbiota transplantation: indications, methods, evidence, and future directions. 2013 , 15, 337	159
785	Fecal Bacteriotherapy for Recurrent Clostridium difficile Infection: What's Old Is New Again?. 2013 , 15, 101-3	6
784	Biological Control by Microorganisms. 2013 ,	4
783	[Chronic critically ill patients from a gastroenterological perspective]. 2013 , 108, 285-9	
782	Murine models to study Clostridium difficile infection and transmission. 2013 , 24, 94-7	19
781	Therapeutic approaches for Clostridium difficile infections. 2013 , 30, 9A.3.1-9A.3.9	4
780	Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options. 2013 , 48, 995-1009	54
779	The role of diet in triggering human inflammatory disorders in the modern age. 2013 , 15, 765-74	27
778	Le microbiote intestinal est lâ�avenir de la multir�sistance bact�rienne. 2013 , 15, 166-177	1
777	Int�t et technique de la transplantation f�cale. 2013 , 15, 187-192	

776	Fecal microbiota transplantation and donor standardization. 2013 , 21, 443-5	31
775	Function of the microbiota. 2013 , 27, 5-16	70
774	Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. 2013 , 108, 1620-30	254
773	Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics for <i>Clostridium difficile</i> and beyond. 2013 , 7, 615-28	16
772	<i>Clostridium difficile</i> Infection. 2013 , 97, 523-36, ix	14
771	Infectiologie en reanimatie. 2013 ,	
770	The Hologenome Concept: Human, Animal and Plant Microbiota. 2013 ,	42
769	Treatment approaches including fecal microbiota transplantation for recurrent <i>Clostridium difficile</i> infection (RCDI) among infectious disease physicians. 2013 , 24, 20-4	49
768	Meta-analyses of studies of the human microbiota. 2013 , 23, 1704-14	289
767	Microbial ecosystems therapeutics: a new paradigm in medicine?. 2013 , 4, 53-65	87
766	Therapeutic potential of fecal microbiota transplantation. 2013 , 145, 946-53	395
765	The adoptive transfer of behavioral phenotype via the intestinal microbiota: experimental evidence and clinical implications. 2013 , 16, 240-5	141
764	Fecal transplant: a safe and sustainable clinical therapy for restoring intestinal microbial balance in human disease?. 2013 , 27, 127-37	73
763	[<i>Clostridium difficile</i> infections - still a major challenge]. 2013 , 155, 57-9	
762	Metagenomics for pathogen detection in public health. 2013 , 5, 81	127
761	<i>Clostridium difficile</i> infection in children: a comprehensive review. 2013 , 29, 967-84	40
760	Duodenal infusion of donor feces for recurrent <i>Clostridium difficile</i> . 2013 , 368, 407-15	2430
759	Infection: treating recurrent <i>C. difficile</i> infection-the challenge continues. 2013 , 10, 10-1	3

758	Reply to Konstantinov and Peppelenbosch. 2013 , 144, e20-1	3
757	Fecal Bacteriotherapy for Clostridium difficile Infections âIts Time Has Come. 2013 , 35, 119-124	2
756	Fecal microbiota transplant for recurrent Clostridium difficile infection: Mayo Clinic in Arizona experience. 2013 , 88, 799-805	42
755	Infant botulism: first two confirmed cases in Slovenia and literature review. 2013 , 17, 651-6	4
754	Intestinal colonization resistance. 2013 , 138, 1-11	323
753	Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. 2013 , 1, 3	503
752	Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. 2013 , 108, 478-98; quiz 499	1147
751	American Journal of Gastroenterology Lecture: Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. 2013 , 108, 177-85	125
750	Fecal microbiome transplantation for recurrent Clostridium difficile infection: report on a case series. 2013 , 19, 22-6	90
749	Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. 2013 , 108, 500-8	619
748	Medicines from microbiota. 2013 , 31, 309-15	102
747	Host-microbiota interaction and intestinal stem cells in chronic inflammation and colorectal cancer. 2013 , 9, 409-22	16
746	The role of the bacterial microbiome in lung disease. 2013 , 7, 245-57	251
745	Genetically programmable pathogen sense and destroy. 2013 , 2, 715-23	89
744	Fecal microbiota transplantation--an old therapy comes of age. 2013 , 368, 474-5	96
743	Fecal microbiota transplantation: a new standard treatment option for Clostridium difficile infection. 2013 , 11, 447-9	18
742	An overview of fecal microbiota transplantation: techniques, indications, and outcomes. 2013 , 78, 240-9	158
741	Therapy of Clostridium difficile infection: perspectives on a changing paradigm. 2013 , 14, 2375-86	3

740	Treatment of infection: recent trial results. 2013 , 3, 875-886	4
739	Microbiome in human health and disease. 2013 , 96, 153-70	17
738	Fecal microbiota transplantation: past, present and future. 2013 , 29, 79-84	228
737	Current world literature. 2013 , 29, 92-105	
736	Moving fecal microbiota transplantation into the mainstream. 2013 , 28, 589-98	10
735	The intestinal microbiota and susceptibility to infection in immunocompromised patients. 2013 , 26, 332-7	88
734	Fecal microbiota transplantation: an innovative approach to treating Clostridium difficile disease. 2013 , 26, 46-9	5
733	Faecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection: current promise and future needs. 2013 , 29, 628-32	21
732	Important clinical advances in the understanding of Clostridium difficile infection. 2013 , 29, 42-8	24
731	Candida albicans and Enterococcus faecalis in the gut: synergy in commensalism?. 2013 , 4, 409-15	35
730	Clostridium difficile: biological therapies. 2013 , 26, 454-60	8
729	Recent trends in the epidemiology and treatment of C. difficile infection in children. 2013 , 25, 116-21	26
728	Fecal transplantation: re-discovering the value of stool. 2013 , 25, 618-23	2
727	Current world literature. 2013 , 26, 484-92	
726	Fecal microbiota transplantation and emerging treatments for Clostridium difficile infection. 2013 , 26, 498-505	8
725	Clostridium difficile: New Challenges for an Old Foe. 2013 ,	1
724	The host immune response to Clostridium difficile infection. 2013 , 1, 19-35	46
723	Hot topics in gut microbiota. 2013 , 1, 311-8	34

722	The microbiome and Clostridium difficile infection. 2013 , 46-59		
721	Fecal microbiota transplantation: the state of the art. 2013 , 5, e13		21
720	Infections digestives ^ Clostridium difficile: diagnostic et traitement. 2013 , 441-460		
719	Fame and future of faecal transplantations--developing next-generation therapies with synthetic microbiomes. 2013 , 6, 316-25		50
718	Orthologues, Paralogues and Horizontal Gene Transfer in the Human Holobiont. 2013 ,		3
717	Quantifying the impact of storage procedures for faecal bacteriotherapy in the critically endangered New Zealand parrot, the kakapo (Strigops habroptilus). 2013 , 32, 620-5		17
716	Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. 2013 , 6, 295-308		457
715	Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. 2013 , 26, 604-30		264
714	High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. 2013 , 4, 125-35		218
713	Fecal Microbiota Transplantation: A Novel Way to Treat Gastrointestinal Disorders. 2013 , 19, 83-88		1
712	infection in older adults. 2013 , 9, 403-414		44
711	Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area. <i>Clinical Infectious Diseases</i> , 2013 , 56, 1059-60	11.6	21
710	Cost-effectiveness of generic antiretroviral therapy. 2013 , 158, 776		3
709	Generic antiretrovirals and HIV care in the United States--in response. 2013 , 158, 777-8		
708	Generic antiretrovirals and HIV care in the United States. 2013 , 158, 777		
707	Fecal microbiota therapy for recurrent Clostridium difficile infection in HIV-infected persons. 2013 , 158, 779-80		19
706	Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. 2013 , 19, 2155-65		183
705	Fecal transplant in refractory Clostridium difficile colitis. 2013 , 110, 108-15		16

704	Emerging therapies for Clostridium difficile infection - focus on fidaxomicin. 2013 , 6, 41-53	20
703	Alternative prostate cancer screening strategies--in response. 2013 , 158, 778-9	1
702	Cost-effectiveness of generic antiretroviral therapy--in response. 2013 , 158, 776-7	5
701	[Multidisciplinary approach of Clostridium difficile infection]. 2013 , 30, 165-85	10
700	Causes, consequences, and perspectives in the variations of intestinal density of colonization of multidrug-resistant enterobacteria. 2013 , 4, 129	26
699	The metabolic and ecological interactions of oxalate-degrading bacteria in the Mammalian gut. 2013 , 2, 636-52	47
698	Something old, something new, something borrowed. 2013 , 24, 63-4	1
697	Clinical use of anti-TNF therapy and increased risk of infections. 2013 , 5, 79-99	147
696	Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review. 2014 , 14, 152-75	22
695	Fecal microbiota transplantation for gastrointestinal diseases. 2014 , 63, 69-74	17
694	Physician attitudes toward the use of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection. 2014 , 28, 319-24	36
693	[Fecal microbiota transplantation: first case report in Chile and review]. 2014 , 31, 477-82	4
692	Clostridium difficile infection: guideline-based diagnosis and treatment. 2014 , 111, 723-31	43
691	Infectious etiopathogenesis of Crohn's disease. 2014 , 20, 12102-17	28
690	. 2014 ,	4
689	A case of Clostridium difficile infection complicated by acute respiratory distress syndrome treated with fecal microbiota transplantation. 2014 , 20, 12687-90	4
688	Tipping elements in the human intestinal ecosystem. 2014 , 5, 4344	154
687	Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance. 2014 , 5, 69-84	37

686	Immune-based treatment and prevention of Clostridium difficile infection. 2014 , 10, 3522-30	11
685	Clostridium difficile infection: current, forgotten and emerging treatment options. 2014 , 3, 547-57	4
684	Microbiome manipulation modifies sex-specific risk for autoimmunity. 2014 , 5, 485-93	51
683	Clostridium difficile infection: management strategies for a difficult disease. 2014 , 7, 72-86	35
682	Recurrent Clostridium difficile infection treated with home fecal transplantation: a case report. 2014 , 8, 393	7
681	Far-infrared therapy as a novel treatment for encapsulating peritoneal sclerosis. 2014 , 109, 1957-9	5
680	Assessing control bundles for Clostridium difficile: a review and mathematical model. 2014 , 3, e43	22
679	Synthetic Biology and Therapies for Infectious Diseases. 2014 , 109-180	
678	Diverticulitis after fecal microbiota transplant for C. difficile infection. 2014 , 109, 1956-7	13
677	Faecal microbiota transplantation: from practice to legislation before considering industrialization. 2014 , 20, 1112-8	20
676	Microbial and metabolic interactions between the gastrointestinal tract and Clostridium difficile infection. 2014 , 5, 86-95	50
675	Gut Microbiota in Human Health and Diseases. 2014 , 469-469	
674	Practical implementation of faecal transplantation. 2014 , 20, 1098-105	10
673	Faecal microbiota transplantation. 2014 , 52, 141-4	0
672	Fecal microbiota transplantation in treating Clostridium difficile infection. 2014 , 15, 405-8	9
671	Faecal microbiota transplantation for Clostridium difficile infection. 2014 , 68, 363-8	21
670	Fecal microbial therapy: promises and pitfalls. 2014 , 59, 157-61	12
669	Clostridium difficile infection in the postcolectomy patient. 2014 , 20, 2450-69	12

668	Therapeutic faecal microbiota transplantation: current status and future developments. 2014 , 30, 97-105	80
667	Fecal microbiota transplantation: facts and controversies. 2014 , 30, 34-9	60
666	Fecal transplant for recurrent Clostridium difficile infection in children with and without inflammatory bowel disease. 2014 , 58, 588-92	48
665	Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. 2014 , 48, 693-702	298
664	Fecal microbiota transplantation for Clostridium difficile infection: benefits and barriers. 2014 , 30, 47-53	22
663	Irritable bowel syndrome, inflammatory bowel disease and the microbiome. 2014 , 21, 15-21	44
662	Non-pulmonary Infectious Complications. 2014 , 135-163	
661	Clostridium difficile infection: clinical challenges and management strategies. 2014 , 34, 24-34; quiz 35	16
660	Non-Pulmonary Complications of Critical Care. 2014 ,	
659	Clostridium difficile Infection: Epidemiology, Pathogenesis, Risk Factors, and Therapeutic Options. 2014 , 2014, 916826	55
658	Probiotic use in horses - what is the evidence for their clinical efficacy?. 2014 , 28, 1640-52	41
657	Microbiota abnormalities in inflammatory airway diseases - Potential for therapy. 2014 , 141, 32-9	60
656	Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent Clostridium difficile Infection. 2014 , 12, 1572-6	60
655	Treatment of recurrent Clostridium difficile infection: a systematic review. 2014 , 42, 43-59	58
654	Comment traiter une infection digestive ^ Clostridium difficile en 2014 ?. 2014 , 23, 284-297	0
653	A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. 2014 , 210, 964-72	57
652	Microbial composition analysis of Clostridium difficile infections in an ulcerative colitis patient treated with multiple fecal microbiota transplantations. 2014 , 8, 1133-7	20
651	Beneficial modulation of the gut microbiota. 2014 , 588, 4120-30	166

650	Fæale Mikrobiotatransplantation (âStuhltransplantationâ) 2014 , 9, 148-152	1
649	Enteric Clostridial Infections. 2014 , 352-359.e4	
648	What nurses need to know about fecal microbiota transplantation: education, assessment, and care for children and young adults. 2014 , 29, 354-61	5
647	Gut microbiota modulation: probiotics, antibiotics or fecal microbiota transplantation?. 2014 , 9, 365-73	72
646	Alteration of the intestinal microbiota as a cause of and a potential therapeutic option in irritable bowel syndrome. 2014 , 5, 247-61	31
645	Integrative Weight Management. 2014 ,	2
644	Lactobacillus brevis CD2 inhibits Prevotella melaninogenica biofilm. 2014 , 20, 668-74	26
643	Fecal microbiota transplantation in the treatment of Clostridium difficile infections. 2014 , 127, 479-83	59
642	A review of the economics of treating Clostridium difficile infection. 2014 , 32, 639-50	22
641	The Human Gut Microbiome and Its Role in Obesity and the Metabolic Syndrome. 2014 , 71-105	4
640	Faecal microbiota transplantation and bacteriotherapy for recurrent Clostridium difficile infection: a retrospective evaluation of 31 patients. 2014 , 46, 89-97	45
639	European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. 2014 , 20 Suppl 2, 1-26	748
638	Probiotic actions on diseases: implications for therapeutic treatments. 2014 , 5, 625-34	14
637	Fecal microbiota transplantation: effectiveness, complexities, and lingering concerns. 2014 , 7, 210-4	81
636	From stool transplants to next-generation microbiota therapeutics. 2014 , 146, 1573-1582	129
635	Faecal microbiota transplantation--the Austrian approach. 2014 , 20, 1106-11	15
634	Review of the emerging treatment of Clostridium difficile infection with fecal microbiota transplantation and insights into future challenges. 2014 , 34, 787-98	27
633	Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. 2014 , 306, G310-9	254

632	Bacteria from diverse habitats colonize and compete in the mouse gut. 2014 , 159, 253-66	226
631	Infectious diarrhea: an overview. 2014 , 16, 399	23
630	Clostridium difficile infection: a review of the literature. 2014 , 7S1, S6-S13	27
629	Clostridium difficile infection in diabetes. 2014 , 105, 285-94	18
628	An Overview of the Microbiome and the Effects of Antibiotics. 2014 , 10, 445-450	8
627	Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection. 2014 , 8, 1621-33	128
626	Transcription of two adjacent carbohydrate utilization gene clusters in Bifidobacterium breve UCC2003 is controlled by LacI- and repressor open reading frame kinase (ROK)-type regulators. 2014 , 80, 3604-14	25
625	Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children. 2014 , 39, 1003-32	99
624	Clostridium difficile infection in patients with ileal pouches. 2014 , 109, 941-7	24
623	Human pharyngeal microbiome may play a protective role in respiratory tract infections. 2014 , 12, 144-50	43
622	[Recurrent Clostridium difficile infection. Treatment with duodenal infusion of donor feces]. 2014 , 55, 455-9	2
621	Donor feces infusion for eradication of Extended Spectrum beta-Lactamase producing Escherichia coli in a patient with end stage renal disease. 2014 , 20, O977-8	79
620	Use of Bacillus subtilis PXN21 spores for suppression of Clostridium difficile infection symptoms in a murine model. 2014 , 358, 154-61	12
619	Fecal microbiota therapy: ready for prime time?. 2014 , 35, 28-30	7
618	Fecal microbiota transplantation for management of Clostridium difficile infection. 2014 , 33, 301-7	3
617	Pediatric Fecal Microbiota Transplantation. 2014 , 2, 227-234	1
616	Clostridium difficile infection: prevention, treatment, and surgical management. 2014 , 94, 1335-49	22
615	Fecal microbiota transplantation for Clostridium difficile infection: A surgeon's perspective. 2014 , 25, 163-166	1

614	Clostridium difficile infection in the elderly. 2014 , 30, 79-93	52
613	Faecal transplantation for the treatment of Clostridium difficile infection: a review. 2014 , 43, 201-6	14
612	Faecal transplantation for Clostridium difficile infection. Three cases treated in Italy. 2014 , 46, 475	5
611	[Septic shock due to a community acquired Clostridium difficile infection. A case study and a review of the literature]. 2014 , 61, 219-22	1
610	Personalized therapy with probiotics from the host by TripleA. 2014 , 32, 291-3	9
609	Point sur lâémergence des infections rēdivantes ^ Clostridium difficile chez le sujet gē. 2014 , 14, 26-31	
608	Molecular dialogue between the human gut microbiota and the host: a Lactobacillus and Bifidobacterium perspective. 2014 , 71, 183-203	188
607	Rational Therapy of Clostridium difficile Infections. 2014 , 30, 304-9	7
606	Clostridium difficile and the microbiota. 2014 , 124, 4182-9	142
605	Recurrent Clostridium difficile infections: the importance of the intestinal microbiota. 2014 , 20, 7416-23	31
604	Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease. 2014 , 20, 14805-20	74
603	Fame and Future of Fecal Transplantations: Developing Next-Generation Therapies with Synthetic Microbiomes. 2014 , 339-361	1
602	Fecal microbiota transplantation: a new old kid on the block for the management of gut microbiota-related disease. 2014 , 48 Suppl 1, S80-4	26
601	Leaping Forward in the Treatment of Infection: Update in 2015. 2015 , 22, 259-267	4
600	Approaches and developments in studying the human microbiome network. 2015 , 61, 90-94	1
599	Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. 2015 , 41, 835-43	351
598	Fecal microbiota transplantation. 2015 , 17, 192-194	
597	GI Surgery Annual. 2015 ,	

596	Fecal microbiota transplantation broadening its application beyond intestinal disorders. 2015 , 21, 102-11	142
595	Donor Recruitment for Fecal Microbiota Transplantation. 2015 , 21, 1600-6	87
594	Fecal Microbiota Transplant: Could Your Stool Save a Life?. 2015 , 11, 878-882	
593	WSES guidelines for management of Clostridium difficile infection in surgical patients. 2015 , 10, 38	60
592	Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. 2015 , 42, 470-6	117
591	Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective: clinical efficacy and bacterial viability data. 2015 , 42, 1011-8	84
590	Fecal Microbiota Transplant: Respice, Adspice, Prospice. 2015 , 49 Suppl 1, S65-8	16
589	Diarrhea in solid organ transplant recipients. 2015 , 28, 308-16	37
588	Clostridium difficile infection in the pediatric transplant patient. 2015 , 19, 792-8	10
587	[Fecal microbiota transplantation in recurrent Clostridium difficile infection. Report of one case]. 2015 , 143, 531-5	3
586	Low awareness but positive attitudes toward fecal transplantation in Ontario physicians. 2015 , 26, 30-2	5
585	Mouthguards: does the indigenous microbiome play a role in maintaining oral health?. 2015 , 5, 35	24
584	The Antimicrobial Stewardship Approach to Combating Clostridium Difficile. 2015 , 4, 198-215	11
583	Antimicrobial Use, Human Gut Microbiota and Clostridium difficile Colonization and Infection. 2015 , 4, 230-53	36
582	Fecal Microbiota Transplantation: Expanding Horizons for Clostridium difficile Infections and Beyond. 2015 , 4, 254-66	6
581	Colonization Resistance of the Gut Microbiota against Clostridium difficile. 2015 , 4, 337-57	36
580	Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches. 2015 , 6, 1050	178
579	Fecal microbiota transplantation: current clinical efficacy and future prospects. 2015 , 8, 285-91	24

578	Community Structure and Function of Amphibian Skin Microbes: An Experiment with Bullfrogs Exposed to a Chytrid Fungus. 2015 , 10, e0139848	56
577	Clostridium difficile drug pipeline: challenges in discovery and development of new agents. 2015 , 58, 5164-85	72
576	The art of targeting gut microbiota for tackling human obesity. 2015 , 10, 472	13
575	Multiscale analysis of the murine intestine for modeling human diseases. 2015 , 7, 740-57	5
574	Dramatic reduction in Clostridium difficile ribotype 027-associated mortality with early fecal transplantation by the nasogastric route: a preliminary report. 2015 , 34, 1597-601	57
573	Fecal microbiota transplantation (FMT) for Clostridium difficile infection: focus on immunocompromised patients. 2015 , 21, 230-7	58
572	Contributions of nonhematopoietic cells and mediators to immune responses: implications for immunotoxicology. 2015 , 145, 214-32	9
571	Fecal microbiota transplantation and successful resolution of multidrug-resistant-organism colonization. 2015 , 53, 1986-9	64
570	The microbiome and its pharmacological targets: therapeutic avenues in cardiometabolic diseases. 2015 , 25, 36-44	19
569	Fecal microbiota transplantation for the management of Clostridium difficile infection. 2015 , 29, 109-22	50
568	Treatment of recurrent and severe Clostridium difficile infection. 2015 , 66, 373-86	24
567	Clostridium difficile infection: risk factors, diagnosis and management. 2015 , 13, 121-9	13
566	Media Discourse on the Social Acceptability of Fecal Transplants. 2015 , 25, 1359-71	17
565	The prevention and management of infections due to multidrug resistant organisms in haematology patients. 2015 , 79, 195-207	36
564	Fecal microbiota transplantation for Clostridium difficile infection: back to the future. 2015 , 15, 1001-14	12
563	Faecal microbiota transplantation for Clostridium difficile infection in the United Kingdom. 2015 , 21, 578-82	11
562	Fecal microbiota transplantation in patients with cancer undergoing treatment. 2015 , 19, 111-4	5
561	Clostridium Difficile Infection from a Surgical Perspective. 2015 , 19, 1363-77	27

560	Fecal Microbiota Transplantation Eliminates Clostridium difficile in a Murine Model of Relapsing Disease. 2015 , 83, 3838-46	76
559	The promise of metabolic phenotyping in gastroenterology and hepatology. 2015 , 12, 458-71	48
558	Engineering the Microbiome: a Novel Approach to Immunotherapy for Allergic and Immune Diseases. 2015 , 15, 39	12
557	Humans as Superorganisms: How Microbes, Viruses, Imprinted Genes, and Other Selfish Entities Shape Our Behavior. 2015 , 10, 464-81	41
556	Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. 2015 , 15, 191	108
555	Sequencing and beyond: integrating molecular 'omics' for microbial community profiling. 2015 , 13, 360-72	394
554	[Fecal microbiota transplantation in recurrent Clostridium difficile infections. Framework and pharmaceutical preparation aspects]. 2015 , 73, 323-31	4
553	Current Status of the Treatment of Fulminant Colitis. 2015 , 93, 276-282	
552	Current Status of the Treatment of Fulminant Colitis. 2015 , 93, 276-82	1
551	Pseudomembranous colitis. 2015 , 61, 181-206	64
550	Clostridium difficile infection: New insights into therapeutic options. 2016 , 42, 773-9	2
549	Diagnosis and management of Clostridium difficile infection. 2015 , 36, 31-43	15
548	Recurrent Clostridium difficile infection: From colonization to cure. 2015 , 34, 59-73	60
547	Fecal microbiota transplant to treat recurrent Clostridium difficile infections. 2015 , 35, 51-64; quiz 65	15
546	Berberine blocks the relapse of Clostridium difficile infection in C57BL/6 mice after standard vancomycin treatment. 2015 , 59, 3726-35	31
545	Practice parameters for the management of Clostridium difficile infection. 2015 , 58, 10-24	33
544	Comparison of Clostridium difficile isolates from individuals with recurrent and single episode of infection. 2015 , 33, 105-8	17
543	[Current treatment and epidemiology of Clostridium difficile infections]. 2015 , 36, 596-602	3

542	Fecal microbiota transplantation via nasogastric tube for recurrent clostridium difficile infection in pediatric patients. 2015 , 60, 23-6	50
541	Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)?. 2015 , 27, 19-29	58
540	Diagnosis and treatment of Clostridium difficile in adults: a systematic review. 2015 , 313, 398-408	304
539	The microbiota in inflammatory bowel disease. 2015 , 50, 495-507	152
538	Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome?. 2015 , 9, 781-95	36
537	MHC variation sculpts individualized microbial communities that control susceptibility to enteric infection. 2015 , 6, 8642	94
536	A different kind of "allogeneic transplant": successful fecal microbiota transplant for recurrent and refractory Clostridium difficile infection in a patient with relapsed aggressive B-cell lymphoma. 2015 , 56, 512-4	13
535	Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options. 2015 , 32, 639-47	19
534	The microbiota and microbiome in aging: potential implications in health and age-related diseases. 2015 , 63, 776-81	163
533	Clostridium difficile infection in patients with liver disease: a review. 2015 , 34, 2313-24	24
532	Hospital-acquired infections. 2015 , 33, 528-533	4
531	Persistent and Recurrent Clostridium difficile Colitis. 2015 , 28, 65-9	12
530	[Multiresistant Organisms]. 2015 , 140, 417-25	0
529	C. difficile Infection: Changing Epidemiology and Management Paradigms. 2015 , 6, e99	67
528	Humanized microbiota mice as a model of recurrent Clostridium difficile disease. 2015 , 3, 35	51
527	Fecal microbiota transplantation: A "How-To" guide for nurses. 2015 , 22, 445-451	5
526	[Fecal microbiota transplantation: review]. 2015 , 73, 13-21	4
525	Development of fecal microbiota transplantation suitable for mainstream medicine. 2015 , 13, 246-50	32

524	[Fecal microbiota transplantation]. 2015 , 38, 123-34	5
523	Intestinal microbiota transplantation, a simple and effective treatment for severe and refractory Clostridium difficile infection. 2015 , 60, 181-5	60
522	Faecal microbiota transplantation for recurring Clostridium difficile infection in a patient with Crohn's disease and ileorectal anastomosis. 2016 , 2016,	5
521	20. Fäcale Mikrobiota-Transplantation. 2016 ,	
520	Fecal Microbiota Transplantation and Its Usage in Neuropsychiatric Disorders. 2016 , 14, 231-7	88
519	[Chilean consensus of prevention, diagnosis and treatment of Clostridium difficile-associated diarrhea]. 2016 , 33, 98-118	4
518	Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. 2016 , 22, 2219-41	176
517	Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives. 2016 , 49, 257-65	145
516	Fecal Microbiota Transplantation Using Upper Gastrointestinal Tract for the Treatment of Refractory or Severe Complicated Clostridium difficile Infection in Elderly Patients in Poor Medical Condition: The First Study in an Asian Country. 2016 , 2016, 2687605	23
515	Fecal Transplantation using a Nasoenteric Tube during an Initial Episode of Severe Clostridium difficile Infection. 2016 , 48, 31-5	4
514	Human microbiome studies in Korea. 2016 , 4, 311	4
513	The New Era of Treatment for Obesity and Metabolic Disorders: Evidence and Expectations for Gut Microbiome Transplantation. 2016 , 6, 15	45
512	The Challenge and Potential of Metagenomics in the Clinic. 2016 , 7, 29	26
511	Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients. 2016 , 17,	43
510	Advances in the Microbiome: Applications to Clostridium difficile Infection. 2016 , 5,	17
509	[Fecal microbiota transplantation: indications and perspectives]. 2016 , 32, 991-997	4
508	Changes in Colonic Bile Acid Composition following Fecal Microbiota Transplantation Are Sufficient to Control Clostridium difficile Germination and Growth. 2016 , 11, e0147210	90
507	Faecal microbiota transplantation: a review of FMT as an alternative treatment for Clostridium difficile infection. 2016 , 9, hzw007	4

506	A High Rate of Alternative Diagnoses in Patients Referred for Presumed Clostridium difficile Infection. 2016 , 50, 742-6	29
505	NURSING ASSESSMENT FOR "DO IT YOURSELF" FECAL MICROBIOTA TRANSPLANTATION. 2016 , 39, 60-2	2
504	Long-term microbiota and virome in a Zñich patient after fecal transplantation against Clostridium difficile infection. 2016 , 1372, 29-41	34
503	Fecal Microbiota Transplantation for Treatment of Severe, Recurrent, and Refractory Clostridium difficile Infection in a Severely Immunocompromised Patient. 2016 , 24, 237-240	1
502	Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection. 2016 , 43, 445-57	110
501	Current Understanding of Dysbiosis in Disease in Human and Animal Models. 2016 , 22, 1137-50	300
500	Cost Averted With Timely Fecal Microbiota Transplantation in the Management of Recurrent Clostridium difficile Infection in Alberta, Canada. 2016 , 50, 747-53	17
499	Long-term changes of bacterial and viral compositions in the intestine of a recovered Clostridium difficile patient after fecal microbiota transplantation. 2016 , 2, a000448	37
498	Fecal microbiota transplantation to fight infections and other intestinal diseases. 2016 , 6, e1251380	12
497	Successful Fecal Microbiota Transplantation as an Initial Therapy for Clostridium difficile Infection on an Outpatient Basis. 2016 , 55, 999-1000	5
496	Biomarkers of Gastrointestinal Host Responses to Microbial Infections. 2016 , 663-682	
495	Clostridium difficile Infection. 2016 , 4,	9
494	Luminal Clinical. 2016 , 31 Suppl 2, 156-168	
493	Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. 2016 , 22, 2402-9	106
492	Gastrointestinal Microbiota and Their Contribution to Healthy Aging. 2016 , 34, 194-201	25
491	Principles of DNA-Based Gut Microbiota Assessment and Therapeutic Efficacy of Fecal Microbiota Transplantation in Gastrointestinal Diseases. 2016 , 34, 279-85	20
490	Microbiomes, metagenomics, and primate conservation: New strategies, tools, and applications. 2016 , 199, 56-66	50
489	Clostridium Difficile Infection in Children: A Review. 2016 , 63, e130-e140	27

488	Predictors of Early Failure After Fecal Microbiota Transplantation for the Therapy of Clostridium Difficile Infection: A Multicenter Study. 2016 , 111, 1024-31	83
487	Fecal microbiota transplantation for the intestinal decolonization of extensively antimicrobial-resistant opportunistic pathogens: a review. 2016 , 48, 587-92	71
486	A bug's view of allergic airways disease. 2016 , 19, 69-74	1
485	Patient Perspectives on Fecal Microbiota Transplantation for Clostridium Difficile Infection. 2016 , 5, 155-64	14
484	The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. 2016 , 9, 606-25	104
483	Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. 2016 , 352, 535-8	235
482	Novel perspectives on therapeutic modulation of the gut microbiota. 2016 , 9, 580-93	56
481	Microbiota of the Human Body. 2016 ,	18
480	How to Manipulate the Microbiota: Fecal Microbiota Transplantation. 2016 , 902, 143-53	15
479	A case of multiple recurrence of Clostridium difficile infection with severe hematochezia in an immunocompromised host. 2016 , 42, 31-32	2
478	Inhibition of Clostridium difficile by natural herbal extracts. 2016 , 11, 427-431	7
477	Microbiome in Transplantation. 2016 , 939-949	
476	Clearance of Vancomycin-Resistant Concomitant With Administration of a Microbiota-Based Drug Targeted at Recurrent Infection. 2016 , 3, ofw133	42
475	Bacterial Infections. 2016 , 1038-1062	
474	Clostridium difficile. 2016 ,	2
473	Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection. 2016 , 74,	10
472	A Practical Method for Preparation of Fecal Microbiota Transplantation. 2016 , 1476, 259-67	6
471	Fecal microbiota transplantation for the treatment of Clostridium difficile infection. 2016 , 11, 56-61	34

470	Understanding the canine intestinal microbiota and its modification by pro-, pre- and synbiotics - what is the evidence?. 2016 , 2, 71-94	52
469	Fecal microbiota transplantation in inflammatory bowel disease: the quest for the holy grail. 2016 , 9, 1360-1365	46
468	Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand. 2016 , 46, 479-93	65
467	Any Future for Fecal Microbiota Transplantation as Treatment Strategy for Inflammatory Bowel Diseases?. 2016 , 34 Suppl 1, 74-81	20
466	Clostridium difficile colitis: pathogenesis and host defence. 2016 , 14, 609-20	261
465	An assessment of the future impact of alternative technologies on antibiotics markets. 2016 , 9, 34	4
464	Selected Topics in Anaerobic Bacteriology. 2016 , 4,	1
463	Anaerobes in Biotechnology. 2016 ,	6
462	Advances in Gut Microbiome Research and Relevance to Pediatric Diseases. 2016 , 178, 16-23	10
461	Anaerobes as Sources of Bioactive Compounds and Health Promoting Tools. 2016 , 156, 433-464	9
460	Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in the Elderly: Long-Term Outcomes and Microbiota Changes. 2016 , 61, 3007-3015	44
459	Antibiotics and the Intestinal Microbiome : Individual Responses, Resilience of the Ecosystem, and the Susceptibility to Infections. 2016 , 398, 123-146	22
458	Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial. 2016 , 165, 609-616	344
457	Pectin enhances the effect of fecal microbiota transplantation in ulcerative colitis by delaying the loss of diversity of gut flora. 2016 , 16, 255	43
456	Policy and regulations in light of the human body as a "superorganism" containing multiple, intertwined symbiotic relationships. 2016 , 33, 39-48	8
455	The gut microbiome: Potential innovations for the understanding and treatment of psychopathology.. 2016 , 57, 67-75	4
454	[Clostridium difficile infections in geriatric patients]. 2016 , 49, 743-761	2
453	A single gene of a commensal microbe affects host susceptibility to enteric infection. 2016 , 7, 11606	23

452	Faecal microbiota transplantation: applications and limitations in treating gastrointestinal disorders. 2016 , 3, e000087	41
451	colonization and antibiotics response in PolyFermS continuous model mimicking elderly intestinal fermentation. 2016 , 8, 63	5
450	Fäcale Mikrobiotatransplantation (FMT). 2016 , 12, 409-419	0
449	Does education influence the acceptability of faecal microbiota transplantation in colitis: A cross-sectional study. 2016 , 3, 1233685	3
448	Long-term Follow-up Study of Fecal Microbiota Transplantation for Severe and/or Complicated Clostridium difficile Infection: A Multicenter Experience. 2016 , 50, 398-402	88
447	Is the Lower Gastrointestinal Route Really Preferred Over the Upper Gastrointestinal Route for Fecal Microbiota Transfer?. 2016 , 50, 895	4
446	Increased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohn's Disease. 2016 , 22, 2182-90	128
445	Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent Clostridium difficile infection. 2016 , 8, 47	75
444	Management of candidemia in patients with Clostridium difficile infection. 2016 , 14, 679-85	6
443	Ridinilazole: a novel therapy for Clostridium difficile infection. 2016 , 48, 137-43	32
442	Epidemiology, Diagnosis, and Management of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. 2016 , 22, 1744-54	37
441	Reprogrammable microbial cell-based therapeutics against antibiotic-resistant bacteria. 2016 , 27, 59-71	28
440	Treat Clostridium difficile infection in the elderly based on disease severity and history of recurrence. 2016 , 32, 149-153	
439	Older Is Not Wiser, Immunologically Speaking: Effect of Aging on Host Response to Clostridium difficile Infections. 2016 , 71, 916-22	28
438	Fecal microbiota transplantation: in perspective. 2016 , 9, 229-39	186
437	Fecal Microbiota Transplant. 2016 , 5, 58-70	0
436	Expanded Evidence for Frozen Fecal Microbiota Transplantation for Clostridium difficile Infection: A Fresh Take. 2016 , 315, 137-8	5
435	Novel approaches to treating Clostridium difficile-associated colitis. 2016 , 10, 193-204	5

434	Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies. 2016 , 84, 395-406		28
433	Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study. <i>Clinical Infectious Diseases</i> , 2016 , 62, 596-602	11.6	98
432	Establishing a Fecal Microbiota Transplant Service for the Treatment of Clostridium difficile Infection. <i>Clinical Infectious Diseases</i> , 2016 , 62, 908-14	11.6	67
431	Fecal microbiota transplantation in children: a brief review. 2016 , 80, 2-6		32
430	Does the donor matter? Donor vs patient effects in the outcome of a next-generation microbiota-based drug trial for recurrent Clostridium difficile infection. 2016 , 11, 611-6		12
429	Correlation detection strategies in microbial data sets vary widely in sensitivity and precision. 2016 , 10, 1669-81		365
428	Identification of key taxa that favor intestinal colonization of Clostridium difficile in an adult Chinese population. 2016 , 18, 30-8		46
427	Bacterial Infections of the Small and Large Intestine. 2016 , 171-183		
426	Recurrent Clostridium difficile infection and the microbiome. 2016 , 51, 1-10		19
425	Upper Versus Lower Gastrointestinal Delivery for Transplantation of Fecal Microbiota in Recurrent or Refractory Clostridium difficile Infection: A Collaborative Analysis of Individual Patient Data From 14 Studies. 2017 , 51, 145-150		39
424	A human gut ecosystem protects against C. difficile disease by targeting TcdA. 2017 , 52, 452-465		20
423	Life sciences today and tomorrow: emerging biotechnologies. 2017 , 37, 553-565		3
422	Fecal microbial transplantation as a therapeutic option in patients colonized with antibiotic resistant organisms. 2017 , 8, 221-224		18
421	The Gut Microbiota in Inflammatory Bowel Disease. 2017 , 46, 143-154		50
420	Fecal Microbiota Transplantation. 2017 , 46, 171-185		100
419	Clostridium difficile colitis: A clinical review. 2017 , 213, 565-571		32
418	[Breaking paradigms. Intestinal microbiota transplantation: Preliminary report]. 2017 , 85 Suppl 1, 6-12		2
417	Challenges in fecal donor selection and screening for fecal microbiota transplantation: A review. 2017 , 8, 225-237		55

416	Microbiome engineering: Current applications and its future. 2017 , 12, 1600099	95
415	Randomised clinical trial: faecal microbiota transplantation for recurrent <i>Clostridium difficile</i> infection - fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. 2017 , 45, 899-908	116
414	[Fecal microbiota transplantation]. 2017 , 58, 456-468	8
413	European consensus conference on faecal microbiota transplantation in clinical practice. 2017 , 66, 569-580	520
412	Effect of Aging on the Composition of Fecal Microbiota in Donors for FMT and Its Impact on Clinical Outcomes. 2017 , 62, 1002-1008	26
411	Comparative effectiveness of faecal microbiota transplant by route of administration. 2017 , 96, 349-352	17
410	Tracking microbial colonization in fecal microbiota transplantation experiments via genome-resolved metagenomics. 2017 , 5, 50	51
409	Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With <i>Clostridium difficile</i> Infection. 2017 , 152, 799-811.e7	334
408	Consensus report: faecal microbiota transfer - clinical applications and procedures. 2017 , 45, 222-239	80
407	Microbiota-Based Therapies for <i>Clostridium difficile</i> and Antibiotic-Resistant Enteric Infections. 2017 , 71, 157-178	31
406	How to: Establish and run a stool bank. 2017 , 23, 924-930	90
405	Methods and Reporting Studies Assessing Fecal Microbiota Transplantation: A Systematic Review. 2017 , 167, 34-39	61
404	Limited engraftment of donor microbiome via one-time fecal microbial transplantation in treated HIV-infected individuals. 2017 , 8, 440-450	38
403	Transmission of the gut microbiota: spreading of health. 2017 , 15, 531-543	99
402	Fecal Microbiota Transplant for <i>Clostridium difficile</i> Infection in a Pregnant Patient. 2017 , 129, 507-509	7
401	A Perspective on Brain-Gut Communication: The American Gastroenterology Association and American Psychosomatic Society Joint Symposium on Brain-Gut Interactions and the Intestinal Microenvironment. 2017 , 79, 847-856	18
400	The Yin and Yang of regulatory T cells in infectious diseases and avenues to target them. 2017 , 19, e12746	28
399	Novel Targets for Drug Development. 2017 , 1583-1608	

398	Gut microbiota and IBD: causation or correlation?. 2017 , 14, 573-584	601
397	Update on intestinal microbiota in Crohn's disease 2017: Mechanisms, clinical application, adverse reactions, and outlook. 2017 , 32, 1804-1812	14
396	Results of the implementation of a multidisciplinary programme of faecal microbiota transplantation by colonoscopy for the treatment of recurrent <i>Clostridium difficile</i> infection. 2017 , 40, 605-614	3
395	The Present Status of Fecal Microbiota Transplantation and Its Value in the Elderly. 2017 , 15, 349-362	10
394	Parasites, ghosts and mutualists: a relational geography of microbes for global health. 2017 , 42, 544-558	47
393	Fecal Microbiota Transplant in Severe/Complicated <i>Clostridium difficile</i> Infection. 2017 , 25, 264-267	1
392	Bezlotoxumab for the prevention of <i>Clostridium difficile</i> recurrence. 2017 , 17, 1439-1445	5
391	Results of the implementation of a multidisciplinary programme of faecal microbiota transplantation by colonoscopy for the treatment of recurrent <i>Clostridium difficile</i> infection. 2017 , 40, 605-614	
390	Recent Issues in Pediatric <i>Clostridium difficile</i> Infection. 2017 , 19, 49	5
389	Safety and Efficacy of Fecal Microbiota Transplant for Recurrent <i>Clostridium difficile</i> Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series. 2017 , 92, 1617-1624	39
388	Fecal microbiota transplantation for recurrent <i>clostridium difficile</i> infection in children. 2017 , 74 Suppl 1, S120-S127	11
387	Fecal Microbiota Therapy With a Focus on <i>Clostridium difficile</i> Infection. 2017 , 79, 868-873	6
386	Introducing the sporobiota and sporobiome. 2017 , 9, 38	30
385	Complications, effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for treatment of recurrent infection. 2017 , 5, 868-879	44
384	Chronic Diarrhea. 2017 , 341-350.e1	
383	Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent <i>Clostridium difficile</i> Infection: An Open-Label, Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2017 , 64, 265-271	11.6 110
382	Diagnosis and treatment of <i>Clostridium difficile</i> (<i>C. diff</i>) colitis: Review of the literature and a perspective in gynecologic oncology. 2017 , 144, 428-437	4
381	Fecal microbiota transplantation for infection in patients with ileal pouches. 2017 , 5, 200-207	15

380	Contribution of Microbes to the Health of Humans, Animals, and Plants. 2017 , 115-128		
379	infection in the elderly: an update on management. 2017 , 12, 1799-1809		40
378	Microbial Biofilms and Chronic Wounds. 2017 , 5,		148
377	Host-Microbiota Mutualism in Metabolic Diseases. 2017 , 8, 267		14
376	Microbiota of Chronic Diabetic Wounds: Ecology, Impact, and Potential for Innovative Treatment Strategies. 2017 , 8, 1791		43
375	Clinical Usefulness of Fecal Microbiota Transplantation. 2017 , 23, 149-150		2
374	Faecal microbiota transplantation: a regulatory hurdle?. 2017 , 17, 128		22
373	Is Expansion of Fecal Microbiota Transplantation Available?. 2017 , 70, 211		1
372	FMT in Clostridium difficile and Other Potential Uses. 2017 , 315-326		
371	The Female Urinary Microbiota/Microbiome: Clinical and Research Implications. 2017 , 8,		12
370	The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. 2018 , 24, 1322-1340		64
369	Fecal microbiota transplantation in puppies with canine parvovirus infection. 2018 , 32, 707-711		42
368	Regional variability in fecal microbiota transplantation practices: a survey of the Southern Ontario Fecal Microbiota Transplantation Movement. 2018 , 6, E184-E190		6
367	Successful Fecal Microbiota Transplantation in a Patient with Severe Complicated Infection after Liver Transplantation. 2018 , 12, 76-84		20
366	Smoking and the intestinal microbiome. 2018 , 200, 677-684		115
365	Microbiome and Gut Dysbiosis. 2018 , 109, 459-476		54
364	Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clinical Infectious Diseases</i> , 2018 , 66, e1-e48	11.6	926
363	RUMINANT NUTRITION SYMPOSIUM: Tiny but mighty: the role of the rumen microbes in livestock production. 2018 , 96, 752-770		7

362	Microbial treatment in chronic constipation. 2018 , 61, 744-752		26
361	Microbiologic factors affecting Clostridium difficile recurrence. 2018 , 24, 476-482		26
360	Update of treatment algorithms for Clostridium difficile infection. 2018 , 24, 452-462		70
359	Durability and Long-term Clinical Outcomes of Fecal Microbiota Transplant Treatment in Patients With Recurrent Clostridium difficile Infection. <i>Clinical Infectious Diseases</i> , 2018 , 66, 1705-1711	11.6	29
358	Clostridium difficile cure with fecal microbiota transplantation in a child with Pompe disease: a case report. 2018 , 12, 112		4
357	Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection. <i>Clinical Infectious Diseases</i> , 2018 , 67, 1198-1204	11.6	56
356	Understanding the Intestinal Microbiome in Health and Disease. 2018 , 34, 1-12		39
355	The role of the intestinal microbiome in ocular inflammatory disease. 2018 , 29, 261-266		36
354	Equine faecal microbiota transplant: Current knowledge, proposed guidelines and future directions. 2018 , 30, 151-160		17
353	Faecal microbiota transplantation in clinical practice. 2018 , 67, 196		10
352	New opportunities for managing acute and chronic lung infections. 2018 , 16, 111-120		46
351	Clinical Practice and Infrastructure Review of Fecal Microbiota Transplantation for Clostridium difficile Infection. 2018 , 153, 266-277		27
350	Harnessing Gut Microbes for Mental Health: Getting From Here to There. 2018 , 83, 214-223		94
349	Fecal Microbiota Transplantation: Therapeutic Potential for a Multitude of Diseases beyond. 2017 , 5,		29
348	Mini-Fecal Microbiota Transplantation for Treatment of Clostridium difficile Proctitis Following Total Colectomy. <i>Clinical Infectious Diseases</i> , 2018 , 66, 299-300	11.6	0
347	C. difficile Microbiome Manipulation. 2018 , 153-162		
346	An Intra-gastric Fecal Microbiota Transplantation Program for Treatment of Recurrent Clostridium difficile in Children is Efficacious, Safe, and Inexpensive. 2018 , 194, 123-127.e1		18
345	The Revolving (Bathroom) Door. 2018 , 239-244		

344	Recipe for IBD: can we use food to control inflammatory bowel disease?. 2018 , 40, 145-156	17
343	Fecal Transplantation for Treatment of Clostridium Difficile Infection in Elderly and Debilitated Patients. 2018 , 63, 198-203	25
342	Evolution of the hygiene hypothesis into biota alteration theory: what are the paradigms and where are the clinical applications?. 2018 , 20, 147-155	10
341	Fecal microbiota transplantation: donor relation, fresh or frozen, delivery methods, cost-effectiveness. 2019 , 32, 30-38	37
340	Five years of fecal microbiota transplantation - an update of the Israeli experience. 2018 , 24, 5403-5414	10
339	Metagenomic Approaches for Investigating the Role of the Microbiome in Gut Health and Inflammatory Diseases. 2018 ,	1
338	Recent Advances in Probiotics as Live Biotherapeutics Against Gastrointestinal Diseases. 2018 , 24, 3162-3171	12
337	Fecal microbiota transplantation in recurrent Clostridium difficile infection: the first prospective study of 30 patients in Romania. 2018 , 26, 201-210	
336	Strategies for the Preservation, Restoration and Modulation of the Human Milk Microbiota. Implications for Human Milk Banks and Neonatal Intensive Care Units. 2018 , 9, 2676	18
335	Impact of Amoxicillin-Clavulanate followed by Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential. 2018 , 3,	13
334	The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation. 2018 , 13, e0194904	39
333	Gut Microbiome Dysbiosis and Immunometabolism: New Frontiers for Treatment of Metabolic Diseases. 2018 , 2018, 2037838	123
332	[Fecal microbiota transplantation through colonoscopy for Clostridium difficile recurrent infection. Report of eight cases]. 2018 , 146, 823-830	4
331	Novel Chimeric Protein Vaccines Against Infection. 2018 , 9, 2440	5
330	Commercialized fecal microbiota transplantation provides efficacious treatment of Clostridium difficile infection. 2018 , 50, 864-867	2
329	Transplante de microbiota fecal no tratamento da infecçã por Clostridium difficile recorrenteâUma revisã. 2018 , 11, 051-055	
328	Comparing fecal microbiota transplantation to standard-of-care treatment for recurrent Clostridium difficile infection: a systematic review and meta-analysis. 2018 , 30, 1309-1317	34
327	Understanding the Milk Microbiota. 2018 , 34, 427-438	16

326	Fecal Microbiota Transplantation for the Management of Infection. 2018 , 19, 785-791	5
325	Das Mikrobiom. 2018 , 23, 44-46	
324	Fecal microbiota transplant - a new frontier in inflammatory bowel disease. 2018 , 11, 321-328	31
323	The use of faecal microbiota transplant as treatment for recurrent or refractory <i>Clostridium difficile</i> infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. 2018 , 100 Suppl 1, S1-S31	23
322	Oral Immunization with Nontoxigenic <i>Clostridium difficile</i> Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity against <i>C. difficile</i> Infection in Both Mice and Hamsters. 2018 , 86,	6
321	Fecal Microbiota Transplantation: Therapeutic Potential for a Multitude of Diseases beyond <i>Clostridium difficile</i> . 2018 , 291-308	2
320	Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. 2018 , 67, 292-310	91
319	Fecal Microbiota Transplantation as Therapy for Inflammatory Bowel Disease. 2018 , 319-327	
318	Novel electrospun fibers with incorporated commensal bacteria for potential preventive treatment of the diabetic foot. 2018 , 13, 1583-1594	13
317	Fecal microbiota transplantation in the treatment of <i>Clostridium difficile</i> infection: state of the art and literature review. 2018 , 45, e1609	3
316	Intestinal microbiota in short bowel syndrome. 2018 , 27, 223-228	10
315	Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation. 2018 , 24, 5-14	204
314	Conducting metagenomic studies in microbiology and clinical research. 2018 , 102, 8629-8646	17
313	Why is it so difficult to evaluate faecal microbiota transplantation as a treatment for ulcerative colitis?. 2018 , 16, 209-215	8
312	Standardized Preparation for Fecal Microbiota Transplantation in Pigs. 2018 , 9, 1328	19
311	Liver Transplantation and Gut Microbiota Profiling in a Child Colonized by a Multi-Drug Resistant : A New Approach to Move from Antibiotic to "Eubiotic" Control of Microbial Resistance. 2018 , 19,	4
310	Human microbiome restoration and safety. 2018 , 308, 487-497	27
309	The use of faecal microbiota transplant as treatment for recurrent or refractory infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. 2018 , 67, 1920-1941	153

308	Fecal microbiota transplantation as a potential way to eradicate multiresistant microorganisms. 2018 , 13, e00432	5
307	CLOUD: a non-parametric detection test for microbiome outliers. 2018 , 6, 137	3
306	Intestinal-Based Diseases and Peripheral Infection Risk Associated with Gut Dysbiosis: Therapeutic use of Pre- and Probiotics and Fecal Microbiota Transplantation. 2018 , 197-288	
305	Dysbiosis of the Microbiota: Therapeutic Strategies Utilizing Dietary Modification, Pro- and Prebiotics and Fecal Transplant Therapies in Promoting Normal Balance and Local GI Functions. 2018 , 381-419	2
304	The microbiome in autoimmune diseases. 2019 , 195, 74-85	162
303	Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1351-1358 ^{11.6}	78
302	Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience. 2019 , 19, 501-511	67
301	Microbiome and Melanoma. 2019 , 287-302	
300	therapeutics: guidelines and beyond. 2019 , 6, 2049936119868548	4
299	Recent advances in the treatment of using biotherapeutic agents. 2019 , 12, 1597-1615	6
298	Outcomes of a Multidisciplinary Clinic in Evaluating Recurrent Infection Patients for Fecal Microbiota Transplant: A Retrospective Cohort Analysis. 2019 , 8,	4
297	Establishing a donor stool bank for faecal microbiota transplantation: methods and feasibility. 2019 , 38, 1837-1847	11
296	Gastrointestinal Infections and Clostridium difficile Infection. 2019 , 291-301	
295	Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes?. 2019 , 19, 51	39
294	Gut Microbiome Modulation Based on Probiotic Application for Anti-Obesity: A Review on Efficacy and Validation. 2019 , 7,	23
293	Faecal Transplantation, Pro- and Prebiotics in Parkinson's Disease; Hope or Hype?. 2019 , 9, S371-S379	15
292	Fecal microbiota transplantation for Clostridium difficile infection in Taiwan: Establishment and implementation. 2019 , 52, 841-850	4
291	Trends in intracranial meningioma incidence in the United States, 2004-2015. 2019 , 8, 6458-6467	15

290	Next-Generation Probiotics Their Molecular Taxonomy and Health Benefits. 2019 , 471-500	
289	Microbiome, Autoimmune Diseases and HIV Infection: Friends or Foes?. 2019 , 11,	2
288	Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation. 2019 , 49, 354-363	52
287	Infectious Threats, the Intestinal Barrier, and Its Trojan Horse: Dysbiosis. 2019 , 10, 1676	46
286	An experimental investigation of blob behaviors in lower hybrid wave dominant heating scenarios on EAST. 2019 , 26, 072305	1
285	Adhesive Induced Changes in Cecal Microbiome Alleviated Constipation in Mice. 2019 , 10, 1721	18
284	Are There Potential Applications of Fecal Microbiota Transplantation beyond Intestinal Disorders?. 2019 , 2019, 3469754	15
283	Fecal Microbiota Transplantation: An Update on Clinical Practice. 2019 , 52, 137-143	70
282	Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?. 2019 , 20,	48
281	Disentangling the effect of host genetics and gut microbiota on resistance to an intestinal parasite. 2019 , 49, 873-883	3
280	Degradation of Peptide-Bound Maillard Reaction Products in Gastrointestinal Digests of Glyoxal-Glycated Casein by Human Colonic Microbiota. 2019 , 67, 12094-12104	12
279	Faecal microbiota transplant for eradication of multidrug-resistant Enterobacteriaceae: a lesson in applying best practice? Re: 'A five-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: A Randomized Clinical Trial'. 2019 , 25, 212-213	2
278	Therapeutic Potential of the Microbiome in the Treatment of Neuropsychiatric Disorders. 2019 , 7,	7
277	Initial experience of fecal microbiota transplantation in gastrointestinal disease: A case series. 2019 , 35, 566-571	14
276	Reducing Cost and Complexity of Fecal Microbiota Transplantation Using Universal Donors for Recurrent Clostridium difficile Infection. 2019 , 36, 2052-2061	10
275	Relationship between the microbiome and ocular health. 2019 , 17, 384-392	28
274	The Conceptual Ecology of the Human Microbiome. 2019 , 94, 149-175	15
273	Impact of Gut Microbiota Composition on Onset and Progression of Chronic Non-Communicable Diseases. 2019 , 11,	58

272	Current applications of fecal microbiota transplantation in intestinal disorders. 2019 , 35, 327-331	0
271	HIV and the Gut Microbiota: Composition, Consequences, and Avenues for Amelioration. 2019 , 16, 204-213	51
270	Microbiome and Melanoma. 2019 , 1-16	
269	The microbiome, cancer, and cancer therapy. 2019 , 25, 377-388	355
268	Importance of the intestinal microbiota in ocular inflammatory diseases: A review. 2019 , 47, 418-422	26
267	2019 update of the WSES guidelines for management of () infection in surgical patients. 2019 , 14, 8	59
266	Faecal microbiota transplantation for the decolonization of antibiotic-resistant bacteria in the gut: a systematic review and meta-analysis. 2019 , 102, 174-188	22
265	Fecal Microbiota Transplantation. 2019 , 249-261	1
264	Microbiome, Parkinson's Disease and Molecular Mimicry. 2019 , 8,	43
263	The direct and indirect effects of vancomycin-resistant enterococci colonization in liver transplant candidates and recipients. 2019 , 17, 363-373	4
262	Inflammatory, infectious, and ischemic disorders of the pelvic pouch. 2019 , 30, 10-16	
261	Composition of gut microbiota in patients with toxigenic Clostridioides (Clostridium) difficile: Comparison between subgroups according to clinical criteria and toxin gene load. 2019 , 14, e0212626	17
260	Multiple sclerosis and faecal microbiome transplantation: are you going to eat that?. 2019 , 10, 27-32	6
259	FMT and Microbial Medical Products: Generating High-Quality Evidence through Good Governance. 2019 , 47, 505-523	5
258	Research Progress in Fecal Microbiota Transplantation as Treatment for Irritable Bowel Syndrome. 2019 , 2019, 9759138	8
257	Treatment of Severe and Fulminant Clostridioides difficile Infection. 2019 , 17, 524-533	4
256	Superimposed Clostridium difficile Infection During Checkpoint Inhibitor Immunotherapy-induced Colitis. 2019 , 42, 350-353	10
255	Fecal Microbiota Transplantation After Oral Vancomycin for Recurrent Clostridium difficile Infection. 2019 , 27, 356-359	

254	Fecal microbiota transplantation: Review and update. 2019 , 118 Suppl 1, S23-S31	93
253	Microbial-Based Therapies in the Treatment of Inflammatory Bowel Disease - An Overview of Human Studies. 2018 , 9, 1571	57
252	La microbiota intestinal en el paciente crítico. 2019 , 19, 28-36	
251	Fecal Microbiota Transplantation in the Treatment-Resistant Psychiatric Disorders. 2019 , 369-376	1
250	The Microbiome in Patients With Inflammatory Diseases. 2019 , 17, 243-255	24
249	Me, my self, and the multitude: Microbiopolitics of the human microbiome. 2019 , 22, 325-341	10
248	Faecal freezing preservation period influences colonization ability for faecal microbiota transplantation. 2019 , 126, 973-984	14
247	Analysis of Treatment Outcomes for Recurrent Clostridium difficile Infections and Fecal Microbiota Transplantation in a Pediatric Hospital. 2019 , 38, 32-36	12
246	Faecal microbiota transplantation for Clostridium difficile infection using a lyophilized inoculum from non-related donors: A case series involving 19 patients. 2019 , 66, 69-78	3
245	Cost-effectiveness of Treatment Regimens for Clostridioides difficile Infection: An Evaluation of the 2018 Infectious Diseases Society of America Guidelines. <i>Clinical Infectious Diseases</i> , 2020 , 70, 754-762 ^{11.6}	20
244	Fecal Microbiota Transplant via Endoscopic Delivering Through Small Intestine and Colon: No Difference for Crohn's Disease. 2020 , 65, 150-157	15
243	Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Children. 2020 , 18, 612-619.e134	
242	The gut microbiota in transplant patients. 2020 , 39, 100614	9
241	Expert opinion on fecal microbiota transplantation for the treatment of infection and beyond. 2020 , 20, 73-81	10
240	Scientific frontiers in faecal microbiota transplantation: joint document of Asia-Pacific Association of Gastroenterology (APAGE) and Asia-Pacific Society for Digestive Endoscopy (APSDE). 2020 , 69, 83-91	42
239	The -Resistant Olive Cultivar "Leccino" Has Stable Endophytic Microbiota during the Olive Quick Decline Syndrome (OQDS). 2019 , 9,	23
238	Method comparison for the direct enumeration of bacterial species using a chemostat model of the human colon. 2020 , 20, 2	2
237	Fecal Microbiota Transplant Decreases Mortality in Patients with Refractory Severe or Fulminant Clostridioides difficile Infection. 2020 , 18, 2234-2243.e1	24

236	Roles of microbiota in response to cancer immunotherapy. 2020 , 65, 164-175	21
235	Gut Microbiota and Epilepsy: A Systematic Review on Their Relationship and Possible Therapeutics. 2020 , 11, 3488-3498	12
234	The role of probiotics and prebiotics in the proper functioning of gut microbiota and the treatment of diseases caused by gut microbiota dysbiosis. 2020 , 7, 9-15	0
233	Gut Microbiome Changes in Patients with Active Left-Sided Ulcerative Colitis after Fecal Microbiome Transplantation and Topical 5-aminosalicylic Acid Therapy. 2020 , 9,	18
232	Microbiota Transplant in the Treatment of Obesity and Diabetes: Current and Future Perspectives. 2020 , 11, 590370	15
231	Detoxification of toxin A and toxin B by copper ion-catalyzed oxidation in production of a toxoid-based vaccine against <i>Clostridioides difficile</i> . 2020 , 160, 433-446	2
230	Holo-Omics: Integrated Host-Microbiota Multi-omics for Basic and Applied Biological Research. 2020 , 23, 101414	27
229	Fecal Microbiota Transplantation for Ulcerative Colitis. Are We Ready for Primetime?. 2020 , 49, 739-752	2
228	Evolution of animal immunity in the light of beneficial symbioses. 2020 , 375, 20190601	13
227	Fecal Microbiota Transplantation for multidrug-resistant organism: Efficacy and Response prediction. 2020 , 81, 719-725	8
226	Gold Nanoclusters as an Antibacterial Alternative Against. 2020 , 15, 6401-6408	4
225	Nosocomial Infections: A History of Hospital-Acquired Infections. 2020 , 30, 637-652	9
224	Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than infection: a systematic review and meta-analysis. 2020 , 12, 1-25	23
223	Faecal microbiota transplantation for recurrent infection: An updated systematic review and meta-analysis. 2020 , 29-30, 100642	31
222	No Worm Is an Island; The Influence of Commensal Gut Microbiota on Cyathostomin Infections. 2020 , 10,	2
221	Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms (FERARO): a prospective, randomised placebo-controlled feasibility trial. 2020 , 10, e038847	1
220	Immunomodulatory and Anti-Inflammatory Strategies to Reduce Comorbidity Risk in People with HIV. 2020 , 17, 394-404	2
219	Skin microbiota analysis-inspired development of novel anti-infectives. 2020 , 8, 85	17

218	Microbiota in organ transplantation: An immunological and therapeutic conundrum?. 2020 , 351, 104080	2
217	Gut Microbiota Regulates Depression-Like Behavior in Rats Through the Neuroendocrine-Immune-Mitochondrial Pathway. 2020 , 16, 859-869	26
216	A new protectant medium preserving bacterial viability after freeze drying. 2020 , 236, 126454	11
215	Autologous fecal microbiota transplantation for the treatment of inflammatory bowel disease. 2020 , 226, 1-11	17
214	Gut Remediation of Environmental Pollutants. 2020 ,	
213	Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-augmented Clinical Trials. 2020 , 16, 81-88	9
212	Gut Microbiome Modulates Response to Cancer Immunotherapy. 2020 , 65, 885-896	21
211	The microbiome and gynaecological cancer development, prevention and therapy. 2020 , 17, 232-250	74
210	A Deep Learning Approach to Antibiotic Discovery. 2020 , 180, 688-702.e13	430
209	Fecal Microbiota Transplantation: Redefining Surgical Management of Refractory Infection. 2020 , 33, 92-97	6
208	Clinical management of severe, fulminant, and refractory infection. 2020 , 18, 323-333	2
207	Le transfert de microbiote fœtal: quel potentiel thérapeutique dans le traitement des maladies métaboliques?. 2020 , 34, 108-115	
206	Ursodeoxycholic Acid (UDCA) Mitigates the Host Inflammatory Response during Clostridioides difficile Infection by Altering Gut Bile Acids. 2020 , 88,	17
205	Fecal microbiota transplantation for treatment of patients with recurrent infection. 2020 , 18, 669-676	9
204	From Donor to Patient: Collection, Preparation and Cryopreservation of Fecal Samples for Fecal Microbiota Transplantation. 2020 , 8,	14
203	Emerging role of microbiota in immunomodulation and cancer immunotherapy. 2021 , 70, 37-52	3
202	Gut microbiota contributes towards immunomodulation against cancer: New frontiers in precision cancer therapeutics. 2021 , 70, 11-23	9
201	Superiority of Higher-Volume Fresh Feces Compared to Lower-Volume Frozen Feces in Fecal Microbiota Transplantation for Recurrent Clostridioides Difficile Colitis. 2021 , 66, 2000-2004	1

200	A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group. 2021 , 9, 229-247	19
199	Diarrhea in the pediatric solid organ transplantation recipient: A multidisciplinary approach to diagnosis and management. 2021 , 25, e13886	3
198	Emerging role of Gut-microbiota-brain axis in depression and therapeutic implication. 2021 , 106, 110138	7
197	The role of the microbiome in drug resistance in gastrointestinal cancers. 2021 , 21, 165-176	6
196	Gut microbiota: impacts on gastrointestinal cancer immunotherapy. 2021 , 13, 1-21	12
195	The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation. 2021 , 13, 1966262	0
194	New Developments in the Management of Crohn's Disease. 2021 , 89-114	
193	Healthcare providers' perception of faecal microbiota transplantation with clostridium difficile infection and inflammatory bowel disease: a quantitative systematic review. 2021 , 14, 17562848211042679	
192	Fecal Transplant. 2021 , 1039-1042.e2	
191	Stem Cell Impairment at the Host-Microbiota Interface in Colorectal Cancer. 2021 , 13,	5
190	Fecal microbiota transplantation - where are we?. 2021 , 62, 52-58	0
189	The Human Gut Microbe Suppresses Toxin Release from by Inhibiting Autolysis. 2021 , 10,	3
188	FECAL MICROBIOTES TRANSPLANTATION TECHNOLOGIES: MEDICAL, BIOTECHNOLOGICAL AND REGULATORY ASPECTS. 2021 , 14, 46-56	
187	Interconnections Between the Oral and Gut Microbiomes: Reversal of Microbial Dysbiosis and the Balance Between Systemic Health and Disease. 2021 , 9,	16
186	In Vitro Evaluation of the Effect of Storage at -20°C and Proximal Gastrointestinal Conditions on Viability of Equine Fecal Microbiota Transplant. 2021 , 98, 103360	0
185	Cost-effectiveness analysis of sequential fecal microbiota transplantation for fulminant Clostridioides difficile infection. 2021 , 36, 2432-2440	1
184	How Can Nutrition Help with Gastrointestinal Tract-Based Issues?. 2021 , 37, 63-87	2
183	The Gut Microbiome. 1-36	

182	One dog's waste is another dog's wealth: A pilot study of fecal microbiota transplantation in dogs with acute hemorrhagic diarrhea syndrome. 2021 , 16, e0250344	2
181	Next-generation therapeutic bacteria for treatment of obesity, diabetes, and other endocrine diseases. 2021 , 35, 101504	7
180	Establishment of an In Vitro System of the Human Intestinal Microbiota: Effect of Cultivation Conditions and Influence of Three Donor Stool Samples. 2021 , 9,	2
179	Small Animals Gut Microbiome and Its Relationship with Cancer.	1
178	The relationship between gastrointestinal cancers and the microbiota. 2021 , 6, 498-509	4
177	Fecal microbiota transplant, its usefulness beyond <i>Clostridioides difficile</i> in gastrointestinal diseases. 2021 , 45, 223-223	2
176	The impact of propagule pressure on whole community invasions in biomethane-producing communities. 2021 , 24, 102659	2
175	Lights and Shadows of Microbiota Modulation and Cardiovascular Risk in HIV Patients. 2021 , 18,	0
174	Focus on gut microbiota in age-associated body changes. 2021 , 44-51	
173	Biological Control by Microorganisms. 2, 1-13	
172	Danish national guideline for the treatment of infection and use of faecal microbiota transplantation (FMT). 2021 , 56, 1056-1077	2
171	Gastrointestinal microbiome, what is behind faecal microbiota transplantation?. 2021 , 42, 100898	2
170	Intestinal microbiota: A potential target for enhancing the antitumor efficacy and reducing the toxicity of immune checkpoint inhibitors. 2021 , 509, 53-62	6
169	2'FL and LNT Exert Antipathogenic Effects against ATCC 9689 In Vitro, Coinciding with Increased Levels of and/or Secondary Bile Acids. 2021 , 10,	3
168	Colorectal cancer treatment using bacteria: focus on molecular mechanisms. 2021 , 21, 218	5
167	Gut Microbiota and Type 2 Diabetes Mellitus: Association, Mechanism, and Translational Applications. 2021 , 2021, 5110276	6
166	Influence of Cultivation pH on Composition, Diversity, and Metabolic Production in an In Vitro Human Intestinal Microbiota. 2021 , 7, 156	1
165	Fecal microbiota transplantation for recurrent <i>Clostridioides difficile</i> infection in patients with concurrent ulcerative colitis. 2021 ,	0

164	Procedures for Fecal Microbiota Transplantation in Murine Microbiome Studies. 2021 , 11, 711055	5
163	Clostridioides difficile Infection in Patients with Chronic Kidney Disease: A Systematic Review. 2021 , 2021, 5466656	
162	Drivers and Determinants of Strain Dynamics Following Faecal Microbiota Transplantation.	0
161	Gut Microbiota Manipulation in Foals-Naturopathic Diarrhea Management, or Unsubstantiated Folly?. 2021 , 10,	0
160	Fecal Microbiome Transplantation: An Offhand Recipe for Microbiome Therapeutics. 2022 , 246-246	
159	Clostridium difficile Infection in Surgical Patients. 2021 , 101-113	
158	Fecal Microbiota Transplantation and Microbial Therapeutics for the Treatment of Clostridioides difficile Infection in Pediatric Patients. 2021 , 10, S58-S63	1
157	Microbiomes in Medicine and Agriculture. 2021 , 353-412	
156	Microbiotas are Transmitted Between Holobiont Generations. 2013 , 41-54	1
155	Fecal Microbial Transplant: For Whom, How, and When. 2016 , 405-413	1
154	Prebiotics, Probiotics, and Synbiotics. 2015 , 19-25.e1	2
153	Clostridium difficile in paediatric populations. 2014 , 19, 43-48	4
152	Fecal Microbiota Transplantation: Just a Fancy Trend?. 2015 , 61, 4-7	6
151	High-resolution tracking of microbial colonization in Fecal Microbiota Transplantation experiments via metagenome-assembled genomes.	2
150	The gut microbiome facilitates ecological adaptation in an invasive vertebrate.	3
149	Selected Topics in Anaerobic Bacteriology. 493-535	1
148	Ipilimumab-associated colitis or refractory Clostridium difficile infection?. 2015 , 2015,	6
147	Fecal microbiota transplantation: Historical review and current perspective. 2019 , 7, 423-427	2

146	Fecal Transplants: What Is Being Transferred?. 2016 , 14, e1002503	94
145	Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. 2013 , 8, e81330	135
144	The systemic inflammatory response to Clostridium difficile infection. 2014 , 9, e92578	36
143	[Successful treatment of life-threatening, treatment resistant Clostridium difficile infection associated pseudomembranous colitis with faecal transplantation]. 2012 , 153, 2077-83	5
142	[Detailed methodological recommendations for the treatment of Clostridium difficile-associated diarrhea with faecal transplantation]. 2013 , 154, 10-9	2
141	Initial experience with fecal microbiota transplantation in Clostridium difficile infection - transplant protocol and preliminary results. 2015 , 107, 402-7	13
140	Fecal microbiota transplantation in refractory or recurrent Clostridium difficile infection: a real-life experience in a non-academic center. 2018 , 110, 311-315	5
139	Clostridium Difficile Infection in Inflammatory Bowel Disease Patients. 2019 , 19, 929-935	2
138	Stool therapy may become a preferred treatment of recurrent Clostridium difficile?. 2013 , 19, 4635-7	7
137	Complicated fecal microbiota transplantation in a tetraplegic patient with severe Clostridium difficile infection. 2015 , 21, 3736-40	7
136	Gastroenterologist perceptions of faecal microbiota transplantation. 2015 , 21, 10907-14	25
135	Chinese physicians' perceptions of fecal microbiota transplantation. 2016 , 22, 4757-65	14
134	Therapies to modulate gut microbiota: Past, present and future. 2020 , 26, 777-788	31
133	Association between the gut microbiota and patient responses to cancer immune checkpoint inhibitors. 2020 , 20, 342	7
132	Two Cases of Refractory Pseudomembranous Colitis that Healed Following Fecal Microbiota Transplantation. 2013 , 84, 395	7
131	Combination of Probiotics and Polysaccharide Alleviates Hepatic Steatosis via Gut Microbiota Modulation and Insulin Resistance Improvement in High Fat-Induced NAFLD Mice. 2020 , 44, 336-348	20
130	Microbiome: Paediatricians' perspective. 2015 , 142, 515-24	27
129	Early Results of Fecal Microbial Transplantation Protocol Implementation at a Community-based University Hospital. 2018 , 10, 47-57	12

128	Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease?. 2014 , 5, 550-9	49
127	Human microbiome: From the bathroom to the bedside. 2015 , 6, 79-85	7
126	Clostridium difficile Infection: What's New?. 2013 , 11, 1	8
125	Long-Term Clinical Outcome of Clostridium difficile Infection in Hospitalized Patients: A Single Center Study. 2014 , 12, 299-305	17
124	Refractory Clostridium difficile Infection Cured With Fecal Microbiota Transplantation in Vancomycin-Resistant Enterococcus Colonized Patient. 2015 , 13, 80-4	22
123	Refractory pseudomembranous colitis that was treated successfully with colonoscopic fecal microbial transplantation. 2016 , 14, 83-8	6
122	Applying fecal microbiota transplantation (FMT) to treat recurrent infections (rCDI) in children. 2018 , 6, e4663	15
121	Fecal microbiota transplantation research output from 2004 to 2017: a bibliometric analysis. 2019 , 7, e6411	6
120	Diets with and without edible cricket support a similar level of diversity in the gut microbiome of dogs. 2019 , 7, e7661	13
119	Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent in cancer patients. 2021 , 12, 6498-6506	0
118	Update on Clostridium difficile. 2013 , 51-62	
117	Pseudobezoars: Technology Progress and New Prospects as a Medical Platform. 2013 , 05, 10-14	1
116	Prebiotics, Probiotics, Synbiotics, and Phage Therapy. 2013 , 151-167	
115	Economic burden of Clostridium difficile infection. 2013 , 60-80	1
114	Conventional therapeutics for Clostridium difficile infection. 2013 , 94-108	
113	Successful Fecal Transplantation by Enema for Recurrent and Refractory Clostridium difficile Infection. 2013 , 17, 152-156	3
112	Modulation of the Gut Ecosystem in Irritable Bowel Syndrome. 2014 , 55-73	
111	Le Clostridium difficile dans les populations d'âge pédiatrique. 2014 , 19, 49-54	

- 110 Infection in the Patient with Cancer. **2014**, 562-580.e5
- 109 Future Strategies and Research Directions in Nutrition&Infection Interactions That Will Enhance Human Health. **2014**, 377-390
- 108 Relationship of Probiotics, Prebiotics, Synbiotics to Infections, Immunity, and Nutrition. **2014**, 287-308
- 107 Recent Update in Fecal Microbiota Transplantation. **2014**, 50, 265-274 1
- 106 Clostridium difficile Infection. **2015**, 2744-2756.e3 2
- 105 GUT in FOCUS Symposium NOBEL FORUM, Karolinska Institutet, February 2nd 2015. **2015**, 26, 28480
- 104 Feces transplantation for recurrent Clostridium difficile infection: US experience and recommendations. **2015**, 26, 27657 5
- 103 Non-antibiotic management for Clostridium difficile infection. **2016**, 6, 3-11
- 102 Clostridium difficile Infection. 265-294 1
- 101 FECAL MICROBIOTA THERAPY AND ITS POTENTIAL IN MEDICAL PRACTICE. **2016**, 85, 111-120
- 100 Cellulose Nanofibers for Biomedical Applications. **2016**, 213-232 1
- 99 Transplantation of fecal microbiota or probiotics?. **2017**, 6, 19
- 98 Clostridium difficile Infection: Considerations in the Geriatric Population. **2018**, 291-297
- 97 Targeting the Gut Microbiome to Ameliorate Cardiovascular Diseases. **2017**, 23, 166-174
- 96 Review of updated clinical practice guidelines of the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) for Clostridium difficile infection in adults and children (2017). **2018**, 20, 76-124 1
- 95 Other Proctitides. **2019**, 555-570
- 94 Infection with Clostridium difficile from the family doctor perspective. **2019**, 1, 40
- 93 [Updated review of Clostridium difficile infection in elderly]. **2020**, 55, 225-235

92	Topological Data Analysis of Clostridioides difficile Infection and Fecal Microbiota Transplantation. 2020 , 427-446	
91	STRUCTURING A FECAL MICROBIOTA TRANSPLANTATION CENTER IN A UNIVERSITY HOSPITAL IN BRAZIL. 2020 , 57, 434-458	0
90	Impact of gut microbiota on kidney transplantation. 2021 , 36, 100668	1
89	Ursodeoxycholic acid (UDCA) mitigates the host inflammatory response during Clostridioides difficile infection by altering gut bile acids which attenuates NF- κ B signaling via bile acid activated receptors.	0
88	Gut Remediation: Back to the Future. 2020 , 199-217	1
87	Utilization of Faecal Microbiota in Humans and Animals. 2020 , 54, 1-18	
86	Is fecal microbiota transplantation a promising strategy for type 2 diabetes mellitus?. 2020 , 8,	
85	Prebiotics, Probiotics, Synbiotics, and Phage Therapy. 2013 , 151-167	0
84	Microbiotas are Transmitted Between Holobiont Generations. 2013 , 41-54	1
83	[Fecal microbiota transplants in the treatment of pseudomembranous colitis (1958-2013): priority of discovery and thought styles in the academic literature]. 2020 , 27, 859-878	0
82	Intestinal microbiocenosis in patients with recurrent Clostridium difficile infection, ulcerative colitis and irritable bowel syndrome after transplantation of fecal microflora. 2020 , 69-77	
81	Fecal transplantation: clinical realities and prospects in the treatment of metabolic syndrome. 2020 , 183, 102-112	
80	Efficacy of oral fecal bacteriotherapy in rhesus macaques (Macaca mulatta) with chronic diarrhea. 2013 , 63, 71-5	7
79	Clostridium difficile in paediatric populations. 2014 , 19, 43-54	2
78	Intestinal microbiota and the efficacy of fecal microbiota transplantation in gastrointestinal disease. 2014 , 10, 230-7	19
77	Fecal Microbiota Transplantation for Clostridium difficile Infection: The Ochsner Experience. 2014 , 14, 538-44	17
76	Fecal Microbiota Transplantation: A Review of Emerging Indications Beyond Relapsing Clostridium difficile Toxin Colitis. 2015 , 11, 24-32	15
75	Management of Infection. 2016 , 12, 609-616	8

74	Conventional and alternative treatment approaches for infection. 2017 , 11, 1-10	1
73	Evaluation of changes in microbiota after fecal microbiota transplantation in 6 diarrheic horses. 2021 , 62, 1123-1130	1
72	Current and future applications of fecal microbiota transplantation for children. 2021 ,	0
71	The Microbiota in Systemic Lupus Erythematosus: An Update on the Potential Function of Probiotics. 2021 , 12, 759095	4
70	Microbiome-based therapeutics.. 2022 ,	14
69	Gut Dysbiosis and Infection in Neonates and Adults.. 2021 , 12, 651081	1
68	The effect of fecal microbial transplant on intestinal microbial composition in short bowel neonatal piglets.. 2022 ,	0
67	Family Stool Donation Predicts Failure of Fecal Microbiota Transplant for Clostridioides difficile Infection. 2022 , 1, 141-146	
66	The microbial ecology of Escherichia coli in the vertebrate gut.. 2022 ,	2
65	Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea.. 2022 , 28, 28-42	1
64	Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome Patients: An Updated Systematic Review and Meta-Analysis.. 2022 , 45, 11-20	1
63	Exploring rhizo-microbiome transplants as a tool for protective plant-microbiome manipulation. 2022 , 2,	1
62	Preservation by lyophilization of a human intestinal microbiota: influence of the cultivation pH on the drying outcome and re-establishment ability.. 2022 ,	1
61	La asociaci3n entre microbioma intestinal y uve3itis autoinmune. 2022 ,	
60	Simultaneous Daily Fecal Microbiota Transplantation Fails to Prevent Metronidazole-Induced Dysbiosis of Equine Gut Microbiota.	
59	The association between intestinal microbiome and autoimmune uveitis.. 2022 , 97, 264-275	
58	Roles of Microbiota in Cancer: From Tumor Development to Treatment.. 2022 , 2022, 3845104	0
57	Multi-Donor Fecal Microbial Transplantation for Critically Ill Patients: Rationale and Standard Operating Procedure. 2022 , 2, 55-63	0

56	Bile Acids and the Microbiome: Making Sense of This Dynamic Relationship in Their Role and Management in Crohn's Disease.. 2022 , 2022, 8416578	0
55	Cost-effectiveness of fecal microbiota transplantation for first recurrent <i>Clostridioides difficile</i> infection.. <i>Clinical Infectious Diseases</i> , 2022 ,	11.6 0
54	The Microbiome: the Link to Colorectal Cancer and Research Opportunities.. 2022 , 23, 631	
53	Roles of the gut virome and mycobiome in faecal microbiota transplantation.. 2022 ,	6
52	Fecal microbiota transplantation for Carbapenem-Resistant Enterobacteriaceae: A systematic review.. 2022 ,	1
51	Data_Sheet_1.docx. 2019 ,	
50	El trasplante de microbiota fecal es un tratamiento sencillo, efectivo y seguro en el manejo de la infección por <i>C. difficile</i> en la práctica clínica diaria. 2022 ,	0
49	Fecal microbiota transplant, its usefulness beyond <i>Clostridioides difficile</i> in gastrointestinal diseases. 2022 , 45, 223-230	
48	Diet-Based Microbiome Modulation: You are What You Eat. 2022 , 1-46	
47	Host-microbe interactions and outcomes in multiple myeloma and hematopoietic stem cell transplantation.. 2022 ,	2
46	Fecal Microbiota Transplant in Recurrent <i>Clostridium Difficile</i> Infections: A Systematic Review. 2022 ,	
45	Simultaneous daily fecal microbiota transplantation fails to prevent metronidazole-induced dysbiosis of equine gut microbiota.. 2022 , 104004	1
44	Intestinal Microbiota Regulate Certain Meat Quality Parameters in Chicken.. 2022 , 9, 747705	2
43	A framework to trace microbial engraftment at the strain level during fecal microbiota transplantation.	
42	Translating Microbiome Research From and To the Clinic. 2022 , 76,	0
41	Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent <i>Clostridioides difficile</i> infection. 2022 , 14,	2
40	Implications of Gut Microbiota in Epithelialâ€”Mesenchymal Transition and Cancer Progression: A Concise Review. 2022 , 14, 2964	1
39	<i>C. difficile</i> Microbiome Manipulation. 2022 , 181-191	

38	New hope for Parkinson's disease treatment: Targeting gut microbiota.	3
37	Engineering probiotics to inhibit <i>Clostridioides difficile</i> infection by dynamic regulation of intestinal metabolism. 2022 , 13,	5
36	Cancer as microenvironmental, systemic and environmental diseases: opportunity for transdisciplinary microbiomics science. <i>gutjnl-2022-327209</i>	4
35	Fecal microbiota transplantation: a review on current formulations in <i>Clostridioides difficile</i> infection and future outlooks. 2022 , 22, 929-944	1
34	Efficacy and safety of commercialized fecal microbiota transplant for the treatment of recurrent <i>Clostridioides difficile</i> infection. 2022 ,	
33	Global research trends and hotspots of fecal microbiota transplantation: A bibliometric and visualization study. 13,	
32	Correlation between human gut microbiome and diseases. 2022 ,	2
31	Shouhui Tongbian Capsule ameliorates constipation via gut microbiota-5-HT-intestinal motility axis. 2022 , 154, 113627	0
30	Gut microbiome dysbiosis in malnutrition. 2022 ,	1
29	Toxic megacolon after irrational antibiotic treatment of pregnant patient with Covid 19: Case report. 2022 , 9, 1189-1195	0
28	Impact of the gut microbiome on human health and diseases. 2022 , 25-40	0
27	Consideration on the Standardization and Industrialization of Human Microbiome Technologies in Japan. 2022 ,	0
26	The global incidence of adverse events associated with fecal microbiota transplantation in children over the past 20 years: A systematic review and meta-analysis.	0
25	Effects of Cigarette Smoke Exposure on the Gut Microbiota and Liver Transcriptome in Mice Reveal Gut-Liver Interactions. 2022 , 23, 11008	0
24	Drivers and determinants of strain dynamics following fecal microbiota transplantation. 2022 , 28, 1902-1912	2
23	Modulation of the Gut Microbiome to Enhance Immunotherapy Response in Metastatic Melanoma Patients: A Clinical Review.	1
22	Comprehensive bibliometric and visualized analysis of research on fecal microbial transplantation published from 2000 to 2021. 2022 , 21,	0
21	Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for <i>C. difficile</i> Infections Across Academic and Private Clinical Settings. Publish Ahead of Print,	0

- 20 Interaction of microbiome and immunity in tumorigenesis and clinical treatment. **2022**, 156, 113894 ○
- 19 Application and development of fecal microbiota transplantation in the treatment of gastrointestinal and metabolic diseases: A review. **2022**, 0 1
- 18 Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines. **2022**, 78, 21-30 ○
- 17 Microbiome and Metabolome Insights into the Role of the Gastrointestinal-Brain Axis in Parkinson's and Alzheimer's Disease: Unveiling Potential Therapeutic Targets. **2022**, 12, 1222 ○
- 16 Fecal microbiota transplantation in childhood: past, present, and future. ○
- 15 Safety and feasibility of faecal microbiota transplant for major depressive disorder: study protocol for a pilot randomised controlled trial. **2023**, 9, ○
- 14 Gut Microbiome and Immune Responses in Gastrointestinal Cancer. **2023**, 163-179 ○
- 13 The human and animal's malignant melanoma: comparative tumor models and the role of microbiome in dogs and humans. Publish Ahead of Print, ○
- 12 Fecal Microbiota Transplantation. ○
- 11 El trasplante de microbiota fecal es un tratamiento sencillo, efectivo y seguro en el manejo de la infección por C. difficile en la práctica clínica diaria. **2023**, ○
- 10 Modulation of intestinal microbiome: Promising therapies in the treatment of inflammatory bowel disease. **2023**, 57-68 ○
- 9 Role of Microorganisms in Pathogenesis and Management of Autoimmune Retinopathy (AIR). **2022**, 401-423 ○
- 8 Possibilities of Autologous Fecal Microbiota Transplantation in patients with obesity and diabetes mellitus. **2023**, 19, 300-305 ○
- 7 The Evolving Landscape of Fecal Microbial Transplantation. ○
- 6 Treatment Effects of Natural Products on Inflammatory Bowel Disease In Vivo and Their Mechanisms: Based on Animal Experiments. **2023**, 15, 1031 ○
- 5 Fecal microbiota transplantation for induction of remission in Crohn's disease: a systematic review and meta-analysis. **2023**, 38, ○
- 4 Microbiome-Induced Autoimmunity and Novel Therapeutic Intervention. **2023**, 71-90 ○
- 3 The Interaction between Gut Microbiota and Host Amino Acids Metabolism in Multiple Myeloma. **2023**, 15, 1942 ○

- 2 Fecal Microbiota Transplantation in Inflammatory Bowel Disease. **2023**, 11, 1016 ○
- 1 Relevance of biomarkers indicating gut damage and microbial translocation in people living with HIV. 14, ○